Press Releases Arch Biopartners Inc.

Equities

ACHFF

CA03938C1041

Pharmaceuticals

Delayed OTC Markets Other stock markets 18:39:27 17/02/2026 GMT			5-day change	1st Jan Change
0.6425 ^USD	-6.00%		-1.64%	-27.27%

02-09	Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease	CI
01-29	Arch Biopartners Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	CI

Press Releases

02-09	Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease	AQ
01-29	Arch Biopartners : 2025 Q4 Interim Financial Statements	PU
01-16	Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board	AQ
12-17	Arch Biopartners Announces Ethics Approval for St. Michael's Hospital to participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide	AQ
12-16	Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide	AQ
11-19	Arch Biopartners Closes Non-Brokered Private Placement	AQ
11-10	Arch Biopartners Arranges Non-Brokered Private Placement	AQ
11-05	Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia	AQ
17/09/25	Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)	AQ
30/08/25	Arch Biopartners : 2025 Q3 Interim Financial Statements	PU
06/08/25	Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury	AQ
22/07/25	Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)	AQ
31/05/25	Arch Biopartners : 2025 Q2 Interim Financial Statements	PU
23/04/25	Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	AQ
22/04/25	Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)	AQ
14/03/25	Arch Biopartners Closes Non-Brokered Private Placement	AQ
05/03/25	Arch Biopartners Arranges Non-Brokered Private Placement	AQ
04/03/25	Arch Biopartners : 2025 Q1 Interim Financial Statements	PU
18/02/25	Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI)	AQ
03/02/25	Shares for Interest Debt Settlement	AQ
29/01/25	Arch Biopartners : 2024 Q4 Year-end Financial Statements	PU
08/01/25	Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)	AQ
11/11/24	Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	AQ
15/10/24	Arch Biopartners Arranges Non-Brokered Private Placement	AQ
03/10/24	Closes Units for Debt Settlement	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases Arch Biopartners Inc.

Equities

ACHFF

CA03938C1041

Pharmaceuticals

Press Releases

Filters